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Neurons containing the neuropeptide melanin-concentrating hormone (MCH) are mainly
located in the lateral hypothalamus and the incerto-hypothalamic area, and havewidespread
projections throughout the brain. While the biological functions of this neuropeptide are
exerted in humans through two metabotropic receptors, the MCHR1 and MCHR2, only
the MCHR1 is present in rodents. Recently, it has been shown that the MCHergic sys-
tem is involved in the control of sleep. We can summarize the experimental ﬁndings as
follows: (1) The areas related to the control of sleep and wakefulness have a high density
of MCHergic ﬁbers and receptors. (2) MCHergic neurons are active during sleep, espe-
cially during rapid eye movement (REM) sleep. (3) MCH knockout mice have less REM
sleep, notably under conditions of negative energy balance. Animals with genetically inac-
tivated MCHR1 also exhibit altered vigilance state architecture and sleep homeostasis. (4)
Systemically administered MCHR1 antagonists reduce sleep. (5) Intraventricular microin-
jection of MCH increases both slow wave sleep (SWS) and REM sleep; however, the
increment in REM sleep is more pronounced. (6) Microinjection of MCH into the dorsal
raphe nucleus increases REM sleep time. REM seep is inhibited by immunoneutraliza-
tion of MCH within this nucleus. (7) Microinjection of MCH in the nucleus pontis oralis
of the cat enhances REM sleep time and reduces REM sleep latency. All these data
strongly suggest that MCH has a potent role in the promotion of sleep. Although both SWS
and REM sleep are facilitated by MCH, REM sleep seems to be more sensitive to MCH
modulation.
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INTRODUCTION
Sleep occupies approximately one-third of human’s life. Sleep is
not a homogeneous process. In most mammals two sleep states are
recognized: slow wave sleep (SWS) and the rapid eye movements
(REM) sleep. Wakefulness, SWS, and REM sleep are differenti-
ated by the electroencephalographic (EEG) activity (synchronized
during SWS,desynchronized duringwakefulness, andREM sleep),
cognition (consciousness during wakefulness and dreams during
REM sleep),muscle activity (atonia during REM sleep), and others
physiological parameters (McCarley, 2007; Torterolo and Vanini,
2010).
In the twentieth century experimental and clinical research
began to unravel the mystery of sleep. Nowadays, the main neu-
ronal networks that are involved in the generation of wakefulness,
SWS, and REM sleep are known (Siegel, 2005; McCarley, 2007;
Szymusiak and McGinty, 2008; Torterolo and Vanini, 2010). The
thalamo-cortical network is the pacemaker for the EEG rhythms
of wakefulness and sleep, and is the scaffold for the cognitive
functions. This network is regulated by the activating (waking-
related) systems located in the basal forebrain, postero-lateral
hypothalamus, and mesopontine reticular formation. While the
preoptic area is critical for SWS generation, the mesopontine
region contains the “necessary and sufﬁcient” neuronal networks
for REM sleep generation.
Several neurotransmitters and neuromodulators such as acetyl-
choline (ACh), noradrenaline (NA), dopamine, serotonin, his-
tamine, adenosine, and hypocretins, have been involved in the
control of sleep and wakefulness (Jones, 2005; McCarley, 2007;
Torterolo and Vanini, 2010). Do melanin-concentrating hormone
(MCH), and MCHergic system play a role in the control of sleep?
Is MCH a sleep factor? So far, about 1000 papers related to MCH
have been published. Notwithstanding this, only a relatively small
number of publications associate MCH with sleep. In this review
article we evaluate the data on MCH and sleep, and give our point
of view of how the MCHergic system might regulate behavioral
states.
MELANIN-CONCENTRATING HORMONE
In mammals, MCH is a cyclic neuropeptide with 19 aminoacids
that has been found predominantly in neurons localized in the
lateral hypothalamus and incerto-hypothalamic area (Kawauchi
et al., 1983; Skoﬁtsch et al., 1985; Bittencourt et al., 1992).
Originally, MCH was described as a circulating hormone iso-
lated from salmon pituitaries, where it induces the aggregation of
melanin granules in melanophores; this action results in a pale
skin color (Kawauchi et al., 1983). This mechanism lets the ani-
mal to camouﬂage in response to the background color of the
environment or in response to stress. This effect is opposite to
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the pigment-dispersing effect of alpha-melanocyte stimulating
hormone (α-MSH). Subsequently,MCHwas identiﬁed in rat brain
using immunohistochemical techniques (Skoﬁtsch et al., 1985;
Bittencourt et al., 1992).
MCH structure is identical in all mammals analyzed to date,
including mice, rats, rabbits, and humans (Saito and Nagasaki,
2008). MCH is generated by the cleavage of a precursor of
165 amino acids, the prepro-MCH (ppMCH). ppMCH con-
tains other peptides in addition to MCH, designated as neu-
ropeptide EI (NEI) and neuropeptide GE (NGE; Bittencourt and
Celis, 2008). In addition, the precursor may potentially give rise
to an alternative splice variant termed MCH-gene-overprinted-
polypeptide (MGOP), as well as a portion of the antisense-RNA-
overlapping-MCH (AROM; Toumaniantz et al., 1996; Borsu et al.,
2000).
MCH RECEPTORS AND SIGNALING MECHANISMS
Several research groups almost simultaneously discovered the ﬁrst
MCH receptor in 1999. It was found to be an orphan G-protein
coupled receptor, named SLC-1 (Bachner et al., 1999; Cham-
bers et al., 1999; Lembo et al., 1999; Shimomura et al., 1999).
Because MCH was the only ligand from rat brain extract that
activated rat or human SLC-1 receptor, it was named MCHR1.
In 2001, another MCH receptor was identiﬁed. This receptor
was termed MCHR2 and has a 38% sequence homology with
MCHR1 (Hill et al., 2001; Mori et al., 2001; Sailer et al., 2001).
The binding of MCH to MCHR1 activates diverse intracellular
signaling pathways by coupling to Gi, Gq, and Go proteins, while
MCHR2 is known to couple to the Gq protein (Hawes et al., 2000;
Sailer et al., 2001).
ANATOMY OF THE MCHergic SYSTEM
LOCATION OF THE MCHergic NEURONS
In their classical paper Bittencourt et al. (1992) described that
the ppMCH mRNA as well as MCH were localized in neurons of
the lateral hypothalamic area, and the incerto-hypothalamic area
of the rat. MCHergic neurons are distributed continuously in a
rostrocaudal extent approximately from the level of the caudal
aspect of the paraventricular nucleus to just beyond the mam-
millary recess in rat, cats, and humans (Bittencourt et al., 1992;
Mouri et al., 1993; Torterolo et al., 2006). Photomicrographs of
the MCHergic neurons in the tuberal hypothalamic region of the
cat are shown in Figure 1.
A small number of MCH-containingneuronswas also observed
in the olfactory tubercle and pontine reticular formation in the rat,
as well as in the laterodorsal tegmental (LDT) nucleus and preop-
tic area of female and lactating rats, respectively (Bittencourt et al.,
1992; Rondini et al., 2007, 2010).
PROJECTIONS OF THE MCHergic NEURONS
MCHergic neurons project widely throughout the central nervous
system (CNS; Bittencourt et al., 1992). Because of their impor-
tance in the control of the sleep–wake cycle, we highlight the
projections toward the thalamus, the tubero-mammillar nucleus
of the hypothalamus, the preoptic area of the hypothalamus,
the ventral tegmental area, the periaqueductal gray, the locus
coeruleus (LC), the nucleus pontis oralis (NPO), the laterodorsal
FIGURE 1 | MCHergic neurons are located in the hypothalamus of the
cat. (A) Low magniﬁcation photomicrographs that exhibit MCHergic
neurons at the tuberal level of the hypothalamus. (B–E)The insets in (A) are
shown at higher magniﬁcation. These photomicrographs show MCHergic
neurons of the dorsal hypothalamic area (B), the perifornical region (C,D),
and the lateral hypothalamic area (E). (F)Two MCHergic neurons are shown
at high magniﬁcation. The photomicrographs were taken from 20-μm-thick
sections that were processed for immunoﬂuorescence. FITC was used as
ﬂuorescent agent. Fx, fornix; 3V, third ventricle. Calibration bars: (A) 1mm;
(B–E) 100μm; (F) 20μm.This ﬁgure was modiﬁed fromTorterolo et al.
(2006).
and pedunculopontine tegmental (LDT–PPT) nuclei, and the dor-
sal raphe (DR) nucleus. Furthermore, projections to other struc-
tures such as the cerebral cortex, amygdala, and motor nuclei have
been described (Bittencourt et al., 1992; McGregor et al., 2005;
Elias et al., 2008; Torterolo et al., 2009).
DISTRIBUTION OF THE MCH RECEPTORS
MCH receptors are distributed in diverse areas of the CNS. The
MCHR1 is present in all mammals studied to date, while the
MCHR2 is functional in dogs, ferret, rhesus monkey, and humans
but is a pseudogene in rodents (Tan et al., 2002).
There is a widespread distribution of the MCHR1 mRNA,
and like the MCHergic ﬁbers, this receptor is present in limbic
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structures and in areas related to the control of sleep and
wakefulness. MCHR1 have been detected also in several peripheral
organs (Chung et al., 2009).
The distribution of MCHR2 nearly overlaps with that of
MCH1R, but the latter shows higher relative levels of density and a
wider distribution pattern (Hill et al., 2001; Mori et al., 2001). The
function of MCHR2 remains unknown due to the lack of available
animal models.
MCH: VOLUME CONDUCTION THROUGH THE CEREBROSPINAL FLUID
(CSF)?
As it is the case with the central actions of oxytocin (Veening
et al., 2010), it is likely that some of its biological effects are pro-
duced by volume conduction, through a neuro-humoral pathway
via the CSF (Torterolo et al., 2008). In a recent report, Veening
and Barendregt (2010) stated that the CSF system, in addition to
provide nutrients to and remove waste products from the brain,
contains message molecules in the form of actively released neu-
roactive substances. The authors suggested that this special formof
volume transmission is a way to broadcast coordinated messages
to a variety of brain areas and may underlay changes in behavioral
states (Veening and Barendregt, 2010).
MCHergic ﬁbers are lying close the ventricle walls of the cat (P.
Torterolo, unpublished observation) and MCH is present in the
CSF (Quintela et al., 2010).At the level of theDR,we demonstrated
that tanycytes lining the ﬂoor of the fourth ventricle show positive
immunoreactivity for MCH, and that their long basal processes
are closely related to serotonergic neurons of the DR (Torterolo
et al., 2008). The tanycytes are specialized ependymal cells that
uptake substances from the CSF and release them to the underly-
ing neuropil (Rodriguez et al., 2005). Since serotonergic neurons
of the DR have a fundamental role in the control of REM sleep
(Monti, 2010a, 2010b), MCH could modulate the serotonergic
activity and REM sleep through this type of volume conduction
(see below).
MCHergic SYSTEM. FUNCTIONAL CONSIDERATIONS
NEUROTRANSMITTERS THAT CO-LOCALIZE WITH MCH
In addition to the neuropeptides derived from the ppMCH, other
neurotransmitter and neuromodulators have been described to
co-localize with MCH. Elias et al. (2001) have demonstrated that
the anorexinergic cocaine- and amphetamine-regulated transcript
(CART), is co-expressed in 95% of the MCHergic neurons of the
zona incerta and in 70% of MCH-positive neurons of the lat-
eral hypothalamus of the rat. MCHergic neurons that co-localize
with CART send ascending projections toward the septum and
hippocampus, whereas the non-CART MCHergic neurons send
descending projections toward the brainstem and spinal cord
(Hanriot et al., 2007). In addition, all the MCHergic neurons
express the novel hypothalamic molecule nesfatin-1 that also
suppresses feeding (Fort et al., 2008).
Recently, utilizing MCH immunohistochemistry and in situ
hybridization to detect GAD67 mRNA, Sapin et al. (2010) demon-
strated that 85% of the MCHergic neurons of the tuberal region of
the hypothalamus are also GABAergic. Besides, MCH and GABA
co-localize in the LDT and medial preoptic area (Rondini et al.,
2007, 2010).
ELECTROPHYSIOLOGICAL CHARACTERISTIC OF THE MCHergic
NEURONS
In vitro recordings have shown that theMCHergic neurons present
a resting potential ranging from −62 to −50mV, slightly more
hyperpolarized than nearby hypocretinergic neurons (Guyon
et al., 2009). MCHergic neurons also showed a relatively low
level of spontaneous activity compared with hypocretinergic and
GABAergic neurons of the region.
Glutamate and GABA regulate MCHergic neuronal activity.
Accordingly, both AMPA and NMDA depolarize these neurons
(vandenPol et al., 2004). The activationof group I of metabotropic
glutamate receptors also excite MCHergic neurons (Huang and
van den Pol, 2007). The GABA agonist muscimol hyperpolarizes
MCHergic neurons while there are no data regarding the effect of
GABAB agents Guyon et al. (2009).
SYNAPTIC EFFECTS OF MCH
Studies in lateral hypothalamic neurons in vitro have shown a
predominantly inhibitory effect of MCH both at pre- and postsy-
naptic levels (Gao and van den Pol, 2001). Hence, MCH inhibited
the synaptic activity of both glutamatergic and GABAergic inputs
to lateral hypothalamic neurons. In addition, MCH reduced the
amplitude of glutamate-evoked currents and the amplitude of
miniature excitatory currents, indicating an inhibitory modu-
lation of postsynaptic glutamate receptors. Furthermore, MCH
attenuated L-, N-, and P/Q-type calcium of calcium voltage-
activated currents (Gao and van den Pol, 2002).
MCHergic neurons express MCHR1 autoreceptors; by this
mean the neuropeptide inhibits MCHergic neurons via a depres-
sion of voltage-dependent calcium channels without affecting
the resting potential (Huang et al., 2007). Therefore, MCHergic
neurons would exert a negative feedback on their own activity.
ROLE OF MCH IN THE CONTROL OF ENERGY HOMEOSTASIS
AND MOOD
The high conservation of MCH structure along phylogeny sug-
gests that this neuropeptide is involved in important physiological
processes. The lateral hypothalamic area, where the MCHergic
neurons are mainly located, is an integrative region par excellence.
This region has been implicated in a wide variety of functions,
such as energy homeostasis, wakefulness and sleep, regulation of
motor activity, motivation, and reward (Bernardis and Bellinger,
1996). MCHergic neurons seem to be implicated in some of these
functions.
Due to the strong relationship among sleep, energy homeosta-
sis and major depression we will brieﬂy review the role of MCH
in these processes and condition.
There are strong experimental evidences that MCH increases
food intake and reduces energy expenditure such as:
1. Acute infusion of MCH into the lateral ventricles induces
feeding in rodents. Fasting induces an up-regulation of MCH
mRNA expression (Qu et al., 1996).
2. MCH mRNA levels are also elevated in the obese leptin-
deﬁcient ob/ob mice, suggesting that leptin negatively regulates
MCH expression (Qu et al., 1996). In fact, by means of double
knockout mice for MCH and leptin, it was demonstrated that
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MCH is a critical mediator of the leptin-deﬁcient phenotype
(Segal-Lieberman et al., 2003).
3. The stimulating effect of food intake has been conﬁrmed in
transgenic mice, in which an over-expression of MCH causes
obesity (Ludwig et al., 2001), while prepro-MCH knockout
mice (MCH-KO) are hypophagic and lean (Shimada et al.,
1998). Indeed, MCH is the only known hypothalamic peptide
whose genetic deletion results in leanness. In these MCH-KO
mice, an increase in temperature, heart rate, and metabolic rate
occurs along with an increase in energy expenditure (Astrand
et al., 2004). A toxin-mediated genetic cell ablation strategy
using a truncated ataxin-3 has been applied to induce apopto-
sis of MCHergic neurons; these mice developed a late onset
syndrome characterized also by leanness, hypophagia, and
increased energy expenditure (Alon and Friedman, 2006).
4. Mice knockout for the MCHR1 are lean, although in contrast
to MCH-KO mice, they are hyperactive, hyperphagic, and have
altered metabolism (Marsh et al., 2002). In addition, block-
ade of MCHR1 with speciﬁc antagonists has anorectic effects
(Borowsky et al., 2002).
5. The MCHergic neurons are under the direct control of NPY-
containing neurons of the arcuate nucleus; these neurons are
part of the neuronal network that governs feeding and energy
expenditure (van den Pol et al., 2004). Furthermore, periph-
eral signals of energy abundance such as glucose, enhance
MCHergic activity in vitro (Burdakov et al., 2005).
The presence of MCHergic ﬁbers and receptors in the lim-
bic system tends to suggest that the MCHergic system plays a
role in the control of mood and emotion. Borowsky et al. (2002)
have showed that systemic administration of an MCHR1 antag-
onist produces antidepressant effects (Borowsky et al., 2002). We
have also shown that the microinjection of a low dose of MCH
(50 ng) into the DR of the rat evokes a depressive-like behavior
as shown by a signiﬁcant increase in the immobility time as well
as a decrease in climbing behavior in the forced swimming test
(Lagos et al., 2011b). The depressive-like effect induced by MCH
was prevented by systemic pre-treatment with ﬂuoxetine, a selec-
tive serotonin reuptake inhibitor. Consistent with these results, the
immunoneutralization of MCH by microinjection of antibodies
anti-MCH into the DR has antidepressant effects; anti-MCH anti-
bodies decreased the immobility time in the forced swimming
test without modifying the motor activity measured in the open
ﬁeld test.
The above-mentioned data suggest that MCH modulates the
activity of serotonergic DR neurons, and could be involved in the
control of mood. Furthermore, antagonism of the MCHR1 pro-
duces also a decrease in anxiety in animalsmodels (Borowsky et al.,
2002; Chaki et al., 2005).
Additional functions of MCHvia central or peripheralMCHR1
such as the control of reproduction or the immune response have
been also described (Lakaye et al., 2009; Wu et al., 2009).
ROLE OF MCH IN THE CONTROL OF SLEEP AND
WAKEFULNESS
From 2003 on, several investigators have examined the role
of MCH in sleep, and the evidence indicates that it pro-
motes sleep (Torterolo et al., 2003a; Verret et al., 2003;
Willie et al., 2003).
ANATOMICAL CONSIDERATIONS
We mentioned above that MCHergic ﬁbers and receptors are
present in regions related to the control of sleep and wakeful-
ness. In addition, MCHergic neurons have been identiﬁed in key
areas responsible for the generation of wakefulness and REM sleep
such as the LDT (only in female rats), and the pontine reticular
formation (Bittencourt et al., 1992; Rondini et al., 2007). Last but
not least, MCH is present in the tanycytes of the DR of the cat,
where serotonergic REM “OFF” neurons are present (Torterolo
et al., 2008).
RELATIONSHIP WITH HYPOCRETINERGIC NEURONS
Due to the importance of the hypocretinergic system in sleep
physiology and pathology, the interaction between the MCHer-
gic, and the hypocretinergic system is worth to be considered. The
hypocretinergic neurons degenerate in narcolepsy, a paradigmatic
sleep disorder (Nishino et al., 2000; Peyron et al., 2000; Thannickal
et al., 2000). The activity of the hypocretinergic neurons increases
during active wakefulness, and they are believed to be central in
the maintenance of this state (Torterolo et al., 2001, 2003b; Lee
et al., 2005; Mileykovskiy et al., 2005).
A strong relationship exists between hypocretinergic and
MCHergic neurons in the hypothalamus. The MCHergic neurons
are intermingled with hypocretin (also called orexin)-containing
neurons in the lateral hypothalamus, mainly at the tuberal and
tubero-mammillar levels (Torterolo et al., 2006). MCHergic ﬁbers
are in close relationship with hypocretinergic neurons and vice
versa, which tends to indicate the existence of reciprocal synaptic
contacts between both types of cells (Guan et al., 2002; Torterolo
et al., 2006). This fact as well as the presence of hypocretinergic
receptors on MCHergic neurons suggests an important functional
interaction between both systems (Backberg et al., 2002). In fact,
hypocretin increases MCH mRNA expression in hypothalamic
neurons, directly excites MCHergic neurons and increases glu-
tamate release onto them (Bayer et al., 2002; van den Pol et al.,
2004). On the other hand, MCH modulates hypocretin/orexin-
mediated effects on behavioral state and synaptic transmission
in the lateral hypothalamus (Rao et al., 2008). Rao et al. (2008)
demonstrated that the efﬁcacy of glutamatergic synapses on
hypocretinergic neurons is enhanced in MCHR1 knockout mice,
and hypocretin-1-induced ﬁring is facilitated. On the contrary,
in wild-type mice, MCH signiﬁcantly attenuated the hypocretin-
1-induced enhancement of spike frequency in hypocretinergic
neurons, but not its basal activity. Furthermore, in these neu-
rons, MCH attenuated hypocretin-1-induced enhancement of the
frequency of miniature excitatory postsynaptic currents (EPSCs).
These effects imply that MCH exerts a unique inhibitory inﬂuence
on hypocretinergic signaling as a way to ﬁne-tune the output of
these neurons.
Interestingly, hypocretinergic and MCHergic neurons respond
in a different way to most homeostatic signals such as glucose
(Burdakov et al., 2005), or to waking-related neurotransmitters
such as NA (Bayer et al., 2005). In this regard, it is of note that
while hypocretinergic neurons express theα1 adrenergic receptors,
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MCHergic neurons express the α2 adrenergic receptors, which
are related to activation or inhibition of its target, respectively
(Modirrousta et al., 2005).
WAKING AND SLEEP-RELATED MECHANISMS NEUROTRANSMITTERS
REGULATE MCHergic ACTIVITY
Serotonergic neurons of the dorsal and median raphe nucleus, as
well as noradrenergic neurons of the LC are active during wake-
fulness (Monti and Jantos, 2008; Monti, 2010b; Torterolo and
Vanini, 2010). Midbrain dopaminergic neurons are also involved
in the promotion of wakefulness (Monti and Jantos, 2008). On
the other hand, cholinergic neurons are active both during wake-
fulness and REM sleep (Torterolo and Vanini, 2010). All these
neurotransmitters regulate the activity of the MCHergic neurons.
Noradrenaline hyperpolarizes the MCHergic neurons by direct
synaptic actions mediated by the α2 adrenergic receptor (van
den Pol et al., 2004). Furthermore NA has presynaptic effects;
it decreases the frequency of EPSCs and increases the frequency
of miniature inhibitory postsynaptic currents (IPSCs; van den Pol
et al., 2004).
Serotonin hyperpolarizes MCHergic neurons in the presence
of TTX indicating a direct postsynaptic effect (van den Pol et al.,
2004).
Dopamine decreases the excitability of MCHergic neurons by
decreasing themembrane resistancewithoutmodifying the resting
potential (Guyon et al., 2009).
Acetylcholine hyperpolarizesMCHergic neurons throughmus-
carinic receptors and increases GABA release onto these neurons
through nicotinic mechanisms (van den Pol et al., 2004).
Cannabinoids are sleep-promotingneuromodulators (Murillo-
Rodriguez,2008), and they increase theﬁring rate of theMCHergic
neurons.Acting through theCB1 receptor, these substances induce
depolarization of MCHergic neurons and decrease the activity of
nearby GABAergic neurons (Huang et al., 2007).
In summary, extrahypothalamic waking-related neurotrans-
mitters (NA, serotonin, ACh) inhibit MCHergic neurons, thus
suggesting that in order to generate or maintain wakefulness, these
neurons should be inhibited. Notwithstanding this, it is intrigu-
ing that ACh promotes REM sleep and simultaneously inhibits
MCHergic neurons (see below).
MCHergic NEURONAL ACTIVITY DURING WAKEFULNESS AND SLEEP
Harthoorn et al. (2005) have demonstrated an up-regulation of
the content of MCH in hypothalamic neurons during the resting
phase of the light–dark cycle of the rat, when this animal sleeps
more.
Modirrousta et al. (2005), studied the c-fos expression (as an
index of neuronal activity) of the MCHergic neurons after a sleep
rebound that followed a short protocol (3 h) of total sleep depri-
vation in the rat. Although c-fos expression was observed in a
very small proportion of MCHergic neurons (≈3%), the authors
demonstrated that MCHergic neurons were activated during the
sleep rebound (that consisted mainly in SWS) in comparison to
wakefulness. In contrast, almost no MCHergic neurons expressed
c-fos during sleep (mainly SWS) induced by an adenosine receptor
agonist in rats (Satoh et al., 2006). In the cat, we did not observe
Fos immunoreactivity in MCHergic neurons either during a SWS
rebound that followed a short protocol of total sleep deprivation,
or during REM sleep induced by microinjections of carbachol into
the NPO (Torterolo et al., 2006). However, it should be considered
that the occurrence of a false negative is one of the inconveniences
of this technique.
Verret et al. (2003) also studied the c-fos expression in the
MCHergic neurons of the rat during a REM sleep rebound that
followed a prolonged protocol (72 h) of REM sleep deprivation.
The authors observed that in comparison to the waking period,
during the REM sleep rebound a large number of Fos+ cells
were immunoreactive for MCH and almost 60% of the MCH-
containing neuronswere Fos positive. TheMCHergic neurons that
expressed c-fos either did or did not co-localize CART (Hanriot
et al., 2007).
In accordance with the studies mentioned above, MCHergic
neurons did not express c-fos in wakefulness induced by applica-
tion of GABAA antagonists in the lateral hypothalamus (Goutagny
et al., 2005).
Hassani et al. (2009) made use of in vivo extracellular record-
ings of identiﬁed MCHergic neurons of head restrained rats to
describe their activity during the sleep–wakefulness cycle. These
neurons were silent during wakefulness and began to discharge
during the SWS transition; their ﬁring rate slightly increased dur-
ing SWS and reached a maximum during REM sleep. During this
period of time they ﬁred in doublets or groups of spikes, and often
in relation to twitches of the whiskers and muzzle. Furthermore,
the MCHergic neurons discharged in a reciprocal manner to the
hypocretinergic neurons. Although the sleep “ON” pattern of dis-
charge of the neurons that were analyzed was clear, it remains to
know if this is the general pattern of activity of all the hypothal-
amic and extrahypothalamic MCHergic neurons. Besides, due to
the strong relationship of the MCHergic neurons with the con-
trol of energy homeostasis, it would be important to know if in
conditions of positive energy balance there are MCHergic neurons
active during wakefulness, as suggested by the in vitro studies of
Burdakov et al. (2005).
STUDIES ON GENETICALLY MODIFIED MICE
Studies in knockout mice for both MCHR1 and MCH, show that
these animals have an altered sleep architecture (Adamantidis et al.,
2008; Willie et al., 2008).
MCH-KO mice have a reduction in SWS and an increase of
wakefulness during baseline conditions (Willie et al., 2008). In
response to fasting these animals exhibit a marked hyperactivity,
accelerated weight loss, and an exaggerated decrease in REM sleep
compared to the wild-type littermates. The decrease in REM sleep
results from a reduced number of REM sleep bouts. Following 6 h
of sleep deprivation, these animals have a normal sleep rebound.
This data support a role for MCH in vigilance state regulation,
particularly in response to a challenge in energy homeostasis.
Adamantidis et al. (2008) studied the spontaneous sleep and
its homeostatic regulation in mice with deletion of the MCHR1
gene. In contrast to previous data showing that MCH promotes
sleep, the authors described that the lack of functional MCHR1
results in a hypersomnia-like phenotype. In comparison with wild
littermates, these mice exhibit higher amounts of REM sleep dur-
ing the active (dark) phase. Furthermore MCHR-1 knockout mice
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showed a more pronounced rebound of SWS in response to sleep
deprivation. In addition, the authors found that modaﬁnil, a stim-
ulating drug, induced less wakefulness in MCHR1 knockout mice
than in wild-type littermates. Then, these MCHR1 knockout ani-
mals exhibit altered vigilance and sleephomeostasis,but the sign of
the alteration seems the opposite to previous results. The authors
discussed that these unexpected results could be related to the
development of compensatory mechanisms; the resulting adap-
tive changes would oppose those caused by the blockade of the
endogenous peptide.
EFFECT OF MCH ADMINISTRATION ON SLEEP VARIABLES
Intraventricular microinjections of MCH
Intraventricular microinjections of MCH into the active (dark)
phase of the rat, produced a marked increase in REM sleep (up to
200% above control values) and a moderate increase in SWS (up
to 70% of control values; Verret et al., 2003). The increment in
REM sleep time was due to an increase in the frequency of REM
sleep episodes, whereas their duration remained unchanged.
Intracerebral microinjections of MCH
Using cholera toxin subunit-b as a retrograde tracer in cats, we
have demonstrated that ≈15% of the lateral hypothalamic neu-
rons that project to the NPO, contained MCH (Torterolo et al.,
2009). The NPO of the cat (also called medial pontine reticular
formation or perilocus coeruleus α) or its corresponding nucleus
in the rat, which is called the sub-laterodorsal nucleus, is an inte-
gral part of different models of REM sleep, and is considered to
exert executive control over the initiation and maintenance of this
behavioral state (Reinoso-Suarez et al., 2001; Xi et al., 2001; Chase
and Morales, 2005; Siegel, 2005; Fuller et al., 2007; Luppi et al.,
2007; McCarley, 2007). A single injection of a cholinergic agonist,
such as carbachol, generates REM sleep with a very short latency
(down to 30 s) and a duration that can exceed 2 h (Baghdoyan
et al., 1987). Microinjections of MCH within this region produced
a signiﬁcant decrease in REM sleep latency with an increase in
the time the animal spent in this behavioral state. The increment
in REM sleep time was due to a increase of REM sleep episodes
duration and frequency (Torterolo et al., 2009).
As mentioned earlier, the DR has a dense network of MCH-
immunoreactive ﬁbers and tanycytes (Torterolo et al., 2008). In
this respect, we have studied the effect of MCH administration
into the DR on sleep during the light period of the light–dark
cycle of the rat. MCH induced a marked and dose-dependent
increase of the time the animal spent in REM sleep, and also a
moderate increase of SWS; on the other hand, wakefulness was
reduced (Lagos et al., 2009). The increase of REM sleep time was
due to an increment in the frequency of REM sleep bouts, while
the duration of the episodes was notmodiﬁed. Figure 2 shows rep-
resentative hypnograms of an animal microinjected with MCH or
vehicle (control) into the DR.
The blockade of physiologically released-MCH in the DR by
immunoneutralization (microinjections of antibodies anti-MCH)
increased wakefulness and suppressed REM sleep, while SWS
tended to remain unchanged (Lagos et al., 2011a). The decre-
ment in REM sleep time was due to a decrease in the frequency of
FIGURE 2 | Representative hypnograms illustrating the occurrence of
wakefulness and sleep following microinjection of MCH into the
dorsal raphe nucleus.The effects of the vehicle (A), and 100 ng of MCH
(B) are presented. Comparing to control, the hypnogram corresponding
MCH microinjection depicts a substantial increase in the number of REM
sleep episodes. This ﬁgure was modiﬁed from Lagos et al. (2009).
FIGURE 3 | Representative hypnograms illustrating the occurrence of
wakefulness and sleep following microinjection of anti-MCH
antibodies (immunoneutralization) into the dorsal raphe nucleus.The
effects of the vehicle (A) and 1/100 dilution dose of anti-MCH (B) are
presented. Comparing to control, the hypnogram corresponding to
anti-MCH microinjection depicts a substantial decrease in the number of
REM sleep episodes. This ﬁgure was modiﬁed from Lagos et al. (2011a).
REM sleep episodes whereas the duration of the episodes was not
modiﬁed (Figure 3).
Systemic administration of MCHR1 antagonists
Systemic administration of MCHR1 antagonists in rats decreased
SWS and REM sleep time. This treatment also increased
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wakefulness as well as SWS and REM sleep latencies (Ahnaou
et al., 2008). The reduction of REM sleep was related to a smaller
number of REM sleep bouts, while the duration of the REM sleep
episodes was unchanged.
MCH: PROMOTION OF SLEEP AND SUPPRESSION OF WAKEFULNESS
Most of the preceding data strongly suggest that theMCHergic sys-
tem promotes sleep, but especially REM sleep. Indeed, reversible
inactivation by microinjection of a GABAA agonist into the hypo-
thalamic area where the MCHergic neurons are located, strongly
suppresses REM sleep (Lin et al., 1989).
Hypocretinergic neurons
MCH inhibits waking-related hypocretinergic neurons (Rao et al.,
2008), and by this means the MCHergic system may facilitate
SWS and REM sleep. In fact, sleep attacks, sleep onset REM, and
the intrusion of REM sleep-like atonia during wakefulness (cata-
plexy) characterize narcolepsy, where there is a suppression of the
hypocretinergic activity due to a degeneration of the hypocre-
tinergic neurons (Guilleminault and Fromherz, 2005; Mignot,
2005).
Serotonergic neurons
Serotonergic neurons of the DR are active during wakefulness,
reduce their discharge during SWS, and are essentially silent dur-
ing REM sleep (REM-off neurons; Jacobs and Azmitia, 1992).
Furthermore, serotonin release decreases during REM sleep in
diverse brain areas (Portas et al., 2000). Application of 5-HT1A
receptor agonists into the DR facilitates REM sleep occurrence, an
effect mediated by the activation of inhibitory somatodendritic
5-HT1A autoreceptors (Portas et al., 1996; Monti et al., 2002).
The inhibition of serotonergic neurons of the DR following the
microinjection of the GABAA agonist muscimol also increases
REM sleep time (Nitz and Siegel, 1997). This outcome is sim-
ilar to the one obtained following intra-DR microinjections of
MCH (Lagos et al., 2009). In preliminary studies, microinjection
of MCH into the DR of the cat produced similar effects (Devera
et al., 2007).
Based upon the wake-related discharge pattern of serotonergic
neurons it has been suggested that these neurons promote also
wakefulness; in fact, there is strong evidence that the serotonergic
neurons of the DR have a key role in the activation of the EEG
(Dringenberg and Vanderwolf, 1998).
Therefore, it is likely that the microinjection of MCH into the
DR inhibits the serotonergic neurons and by doing so, reduces
wakefulness and increases REM sleep.
GABAergic neurons of the NPO
Due to thepostulated inhibitory actions of MCH,webelieve that in
order to facilitate the generation of REM sleep, MCH must inhibit
the GABAergic “wake-ON” neurons in the NPO, thus allow-
ing the activation of “REM sleep-ON” neurons (Xi et al., 1999;
Luppi et al., 2007; Brown et al., 2008).
Other waking-related neurons
MCHergic neurons project also to other neural structures involved
in the control of sleep and wakefulness including the basal fore-
brain, the tubero-mammillar nucleus of the hypothalamus, the
LDT–PPT, the LC, and the ventrolateral periaqueductal gray
(vlPAG). Interestingly, the bilateral inhibition or lesions of the
vlPAG and nearby areas generates an important increase in REM
sleep amount (Sastre et al., 1996; Vanini et al., 2007; Kaur et al.,
2009); therefore it is expected that MCH would promote REM
sleep when applied onto this region (Peyron et al., 2009). We
believe that MCH promotes sleep (both SWS and REM) acting
not only on the vlPAG, but acting in tandem onto several waking
and sleep-related regions.
MCHergic neurons innervate also the speciﬁc and non-speciﬁc
nuclei of the thalamus, including the reticular nucleus (Bittencourt
et al., 1992). By actions onto these nuclei as well as onto the neo-
cortex, the MCHergic neurons could inﬂuence the EEG rhythms
and behavioral states (Steriade, 2005).
PHYSIOLOGICAL CONSIDERATIONS
Energy conservation and restoration is one of the probable func-
tions of sleep (Benington and Heller, 1995). Thus MCH would
have an integrative role in energy conservation by promoting food
intake, decreasing metabolism, and inducing sleep.
MCH decreases temperature, heart rate, and metabolic rate
by central actions that enhance the parasympathetic/sympathetic
tone ratio and decrease the release of thyroid hormones. Somato-
motor activity is also reduced by MCH (Saito and Nagasaki,
2008). Given the proﬁle of the activity of the MCHergic neu-
rons it is possible that these actions are maximally expressed
during sleep.
In order to conserve energy, MCHergic neurons could be
involved also in the promotion of sleep in accordance with meta-
bolic demands. It is likely that in conditions of energy abundance
such as post-feeding time, MCH would ﬁrst decrease the level of
wakefulness, and then induce sleep. Furthermore, in special cases
when energy conservation is imperative, MCHergic system may
play a critical role. One case is hibernation, where the whole body
metabolism falls to 1–2% of the basal value, and the body tem-
perature could reach the freezing point of water (Heller and Ruby,
2004). Interestingly, the entrance to this state is through SWS.
Another paradigmatic physiological state is lactation, where we
hypothesize that the activity of the MCHergic system would be
very high. In fact, during this condition MCH is expressed in neu-
rons of the medial preoptic area, a critical region for reproductive
control and maternal behavior (Rondini et al., 2010). During the
lactating period in the rat, the animals appear somnolent and the
EEG is synchronized before milk ejection (Lincoln et al., 1980).
Lactation is also associated with an increase in SWS in women
(Blyton et al., 2002). Furthermore, it has been reported an increase
in the amount of REM sleep after delivery (Petre-Quadens and De
Lee, 1974). These authors also showed a gradual decrease in REM
sleep in bottle-feeding mothers compared to breastfeeding moth-
ers where REM sleep values remain high. Therefore, it would be
important to investigate if the cause of this hypersomnia during
lactation is promoted by MCH.
On the other hand,depression of theMCHergic neuronal activ-
ity may mediate the effect of long-term sleep deprivation. This
condition leads to a marked increase in energy expenditure and
body weight loss (Rechtschaffen and Bergmann, 2002). In fact, this
syndrome partly recalls the effect of the deletion of the MCH gene.
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FIGURE 4 |The schematic shows a simple structural model that
proposes a tentative mechanism by which MCH promotes sleep.
During wakefulness MCHergic neurons may be activated during special
conditions such as energy abundance. Inhibiting and facilitating the
activating and somonogenic (SWS and REM sleep neuronal networks)
respectively, MCH would facilitate and maintain sleep.
MCH IN SLEEP: WORKING HYPOTHESIS
Recently, Peyron et al. (2009) suggested that the MCHergic
neurons are inhibited during wakefulness by extrahypothala-
mic waking-related neurons, and during SWS are inhibited by
GABAergic neurons of the sleep-promoting preoptic region. On
the other hand,glutamatergicREMsleep“ON”neurons of the sub-
laterodorsal nucleus would drive the MCHergic neurons. Thus,
according to this proposal the MCHergic neurons are inhibited or
driven by the classical activating or sleep-promoting system.
A complementary view is to consider that MCHergic neurons
play a more active role in the induction of sleep; in other words,
these neurons would drive the sleep-promoting regions instead
of being driven by them. In addition, MCHergic neurons would
inhibit the activating systems and promote sleep. A simple model
is presented in Figure 4.
THE MCHergic SYSTEM IN PATHOLOGY
In spite of the large number of preclinical studies, there are almost
no data regarding the pathophysiology of the MCHergic system.
Preclinical studies have demonstrated that MCH is related to
energy homeostasis and it has been suggested that a dysfunc-
tion of this system could lead to obesity. In fact, there is one
study that reports a trend toward association of several MCHR1
single-nucleotide polymorphisms with an obese phenotype in
independent study groups of obese German children and ado-
lescents (Wermter et al., 2005). Furthermore,MCHR1 antagonists
could be a therapeutic option for treating obesity (Rivera et al.,
2008).
Kokkotou et al. (2008) demonstrated that mice genetically
deﬁcient in MCH have substantially reduced local inﬂammatory
responses in amodel of experimental colitis. Likewise,mice receiv-
ing treatments with an anti-MCH antibody developed attenuated
colonic inﬂammation and survived longer. Furthermore, there
is an increased colonic expression of MCH and its receptor in
patients with inﬂammatory bowel disease, suggesting a role of
MCH in inﬂammatory processes in the intestine (Kokkotou et al.,
2008).
We have mentioned earlier that there is preclinical evidence to
support an increase in MCHergic activity in depression and that
the antagonismof this systemhas antidepressant effects (Borowsky
et al., 2002; Lagos et al., 2011b). In addition to pro-depressive
effects, MCH promotes the occurrence of REM sleep in labora-
tory animals. Interestingly, in patients with a diagnosis of major
depression (where there would be an increase in MCHergic tone),
REM sleep occurrence is increased (Adrien, 2002). Accordingly, it
could be of interest to determine the role of MCH in patients with
depressive disorder.
Postpartum emotional distress or “blues” occurs in about 75–
80% of new mothers about 3–5 days after birth (Lee, 1998). This
“blues” is typically conﬁned to the 1st week postpartum. More
serious forms of maternal depression and postpartum psychosis
occur in less than 10% of new mothers. Regarding the probable
increment in activity of the MCHergic neurons during postpar-
tum and lactation, it would be important to investigate if MCH is
related to these emotional distresses.
As above-mentioned, there is a close anatomical and functional
relationship between hypocretinergic and MCHergic neurons.
Therefore, it is imperative to know how MCHergic neurons func-
tion in narcolepsy, where there is a degeneration of the hypocre-
tinergic neurons; in fact, the malfunction of MCHergic neurons
could play a role in the pathophysiology of this disease.
Parkinson’s disease (PD) but not Huntington’s disease, is
accompanied by decrease in the number of MCHergic neurons
(Thannickal et al., 2007; Aziz et al., 2008). The tentative relation-
ship between a loss of MCHergic activity and some symptoms of
PD has not been studied yet; however, a decrease in the activity
of MCHergic cells could partly explain the high incidence of the
REM sleep behavior disorder in this pathology (Thorpy andAdler,
2005).
CONCLUSIONS AND FUTURE DIRECTIONS
MCHergic neurons constitute a powerful regulatory system with
wide and divergent projection. MCH is involved in the central
regulation of food intake, energy balance, and mood. Recent evi-
dence strongly suggests that MCH has a regulatory role in the
control of sleep,mainly REM sleep. New experimental approaches
are needed to unravel the role of MCH in sleep. Clinical research is
also needed in order to determine the involvement of this peptide
in a number of neuropsychiatric conditions.
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